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INTRODUCTION
As of April 21, 2020, more than 2.5 million cases of 
coronavirus disease 2019 (COVID-19), caused by the SARS-
CoV-2 virus, have been reported in 210 countries and territories, 
with the death toll at 171,810.1 While extensive research is 
underway to evaluate the efficacy of numerous antiviral and 
other immunomodulatory medications against COVID-19, 
chloroquine (CQ) and hydroxychloroquine (HCQ), in particular, 
have gained considerable attention. Data to support the use of 
CQ and HCQ for COVID-19 are limited and inconclusive, as its 
use against SARS-CoV-2 has been demonstrated in vitro and in 
small, poorly controlled, or uncontrolled clinical trials.2-4 
Since being prominently featured in the press as a 
potential COVID-19 therapy, demand for CQ and HCQ has 
exploded. On March 31, 2020, the United States Food and Drug 
Administration added both medications to its drug shortages 
webpage due to a significant surge in demand.5 Soon after, 
the California Department of Consumer Affairs reported that 
healthcare providers were wrongfully hoarding and prescribing 
CQ or HCQ for themselves and family members for COVID-19 
prophylaxis despite a lack of evidence to support this use.6 In 
response, several states have issued emergency restrictions on 
how CQ and HCQ can be dispensed. 
Unfortunately, the media attention and the increase in usage 
of CQ and HCQ do not come without significant consequences. 
Both medications, when taken in overdose, can cause severe, 
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potentially life-threatening effects. On March 23, 2020, an 
Arizona man died after an overdose of chloroquine phosphate, 
formulated as an aquarium cleaner.7 In light of recent events, 
we anticipate emergency departments may see a rise in cases 
of acute and chronic toxicity from CQ and/or HCQ. Here, we 
present a brief overview of the pharmacology of CQ and HCQ, 
manifestations of toxicity, and treatment considerations. 
PHARMACOLOGY & PATHOPHYSIOLOGY 
The structurally related compounds CQ and HCQ have 
historically been used for the prophylaxis or treatment of 
malaria and share many therapeutic and pharmacokinetic 
properties. HCQ differs from CQ only by a hydroxyl group, 
but is considered less potent and is 40% less toxic than CQ 
in animal models (Figure 1).8 Both CQ and HCQ interfere 
with multiple intracellular processes, resulting in antimalarial, 
anti-inflammatory, and immunomodulating effects. The anti-
inflammatory effects are more pronounced in HCQ, making it 
useful for the treatment of rheumatoid arthritis and systemic 
lupus erythematosus.9 
Oral CQ and HCQ are rapidly and completely absorbed 
from the gastrointestinal tract with peak whole blood levels 
reached 1-3 hours after ingestion.10 It is this peak level that 
is responsible for the rapid onset of severe symptoms and 
most correlates with mortality risk in acute overdose.11 Both 
CQ and HCQ are metabolized by cytochrome (CYP) P450 
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What do we already know about this issue?
Chloroquine and hydroxychloroquine have 
gained media attention as possible therapies 
for coronavirus disease 2019, but both can 
cause potentially life-threatening effects. 
What was the research question?
We present an overview of the pharmacology, 
toxicity, and treatment of chloroquine and 
hydroxychloroquine overdose. 
What was the major finding of the study?
Acute toxicity is characterized by direct 
cardiotoxicity. Supportive care is the mainstay 
of treatment.
How does this improve population health?
Clinicians may see a rise in cases of acute 
and chronic toxicity from chloroquine and 
hydroxychloroquine and should be familiar 
with management strategies.
enzymes. Therefore, concomitant use of CYP2C8 (clopidogrel, 
gemfibrozil), and CYP3A4/5 (azole antifungals, ciprofloxacin, 
diltiazem, macrolides, verapamil) inhibitors may raise CQ and 
HCQ blood levels.12 Due to the large volume of distribution 
and strong tissue-binding properties of these drugs, the terminal 
half-life is 5-12 days for CQ and 1-2 months for HCQ.10 Severe 
symptoms generally occur over several hours, but patients can 
have evidence of ongoing toxicity for days following ingestion. 
CQ and HCQ are structural derivatives of quinine and 
share pathophysiologic mechanisms of toxicity. These drugs 
have direct cardiovascular toxicity through blockade of voltage-
dependent sodium and potassium channels.13 This provides 
the cellular mechanism for the observed QRS and QT interval 
prolongation (Figure 2). Hypotension and cardiogenic shock 
are due to direct cardiodepressant effect rather than peripheral 
vasodilation.14 Hypokalemia is common, especially in acute CQ 
overdoses, and is likely due to an intracellular shift in potassium 
and not a true, total-body potassium deficit.15 
CLINICAL MANEFISTATIONS
CQ and HCQ toxicity is rapid in onset and potentially 
life-threatening. Severe effects have been associated with 
ingestion of 5 grams or more of CQ, including systolic blood 
pressure less than 80 millimeters of mercury, QRS complex 
duration of 120 milliseconds or more, and hypokalemia (less 
than 3 millimoles [mmol] per liter [L]). Serum concentrations 
of CQ greater than 8 micrograms (mcg) per milliliter (mL) 
have also been associated with severe poisoning, but CQ or 
HCQ concentrations are unlikely to be readily available during 
initial assessment and management.16 Respiratory depression, 
central nervous system depression, and seizures have also 
been described in acute poisoning.17
The cardiovascular effects of CQ and HCQ may be 
precipitous and are frequently the primary cause of mortality. 
Both drugs act as Vaughan-Williams Class IA antidysrhythmics 
with “quinidine-like” effect. Electrocardiogram (ECG) changes 
due to sodium and potassium channel blockade are evident 
with QRS interval widening, QT prolongation, ST segment 
depressions, atrioventricular block, and the appearance of 
U waves.10 Cardiac dysrhythmias, including ventricular 
tachycardia, ventricular fibrillation, and torsade de pointes may 
result. Hypotension occurs early, is often severe, and progresses 
rapidly to cardiogenic shock.17 
Despite severe effects in large, acute ingestions, CQ and 
HCQ are generally well tolerated at therapeutic doses with 
mild adverse effects. Common effects are nausea, diarrhea, 
anorexia, abdominal cramps, rash, and alopecia.12 Rarely, 
sensorineural deafness, visual disturbances, corneal opacities, 
and irreversible retinopathy can occur with cumulative doses 
exceeding 100 grams, which usually occurs when CQ and HCQ 
are dosed as anti-inflammatories.9 In addition, agranulocytosis, 
aplastic anemia, hypersensitivity reactions, hepatitis, myopathy, 
neuropathy, and cardiomyopathy have been reported with 
chronic use. CQ and HCQ can act as oxidant stressors, resulting 
in hemolysis in patients with G6PD deficiency.10
CLINICAL MANAGEMENT 
Aggressive symptomatic and supportive care is the mainstay 
of treatment for both CQ and HCQ overdose. In addition to 
stabilization of the airway, breathing, and circulation, the patient 
should receive intravenous (IV) access as well as continuous 
cardiac monitoring. Serial ECGs should be obtained to monitor 
for QRS and QT interval prolongation. CQ and HCQ are well 
absorbed by activated charcoal, and thus should be administered 
if the risk for aspiration is low. Additionally, given the life-
threatening nature of CQ and HCQ poisoning, decontamination 
Figure 1. Structural comparison of chloroquine and 
hydroxychloroquine.10
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with gastric lavage can be considered in cases of a large overdose 
and if the patient presents soon after ingestion. A medical 
toxicologist or poison control center should be contacted to assist 
with management. 
Boluses of sodium bicarbonate (1-2 milliequivalents 
per kilogram [kg] IV) should be provided for QRS interval 
prolongation to counteract the effects of sodium channel 
blockade. Of note, the serum alkalinization that results from 
sodium bicarbonate administration may exacerbate the pre-
existing hypokalemia seen from toxicity, which can contribute to 
further dysrhythmias. However, several reports have suggested 
that hypokalemia may be protective in severe CQ poisoning.18-20 
Therefore, replacement of potassium is controversial in the 
setting of acute toxicity, although we believe it would be 
reasonable to treat severe hypokalemia (i.e., < 2 mmol/L). Cases 
of rebound hyperkalemia have been reported once toxicity 
resolves; therefore, serial potassium levels should be obtained.8,19 
Both diazepam and epinephrine have been suggested as 
specific treatments for CQ and HCQ toxicity. In observational 
studies, patients with mixed overdoses of diazepam and 
chloroquine had less toxic effects than those who ingested 
chloroquine alone.11,19 Diazepam is believed to decrease CQ 
and HCQ induced-vasodilation and have central antagonistic, 
anticonvulsant, and antidysrhythmic effects.10 We recommend 
that patients with severe CQ and HCQ symptoms receive high-
dose diazepam therapy (2 milligrams/kg IV over 30 minutes). 
Because high-dose IV epinephrine (0.25 micrograms/kg per 
minutes [mcg/kg/min], increasing by 0.25mcg/kg/min until 
adequate systolic blood pressure) has been the most extensively 
studied in cases of CQ- and HCQ-induced hypotension, 
epinephrine is the vasopressor of choice in these specific 
ingestions.16,21 Additionally, combining high-dose diazepam 
and high-dose epinephrine has shown a potential mortality 
benefit when compared to controls.16 Like sodium bicarbonate, 
high-dose epinephrine may worsen pre-existing hypokalemia. 
Finally, a trial of 20% IV fat emulsion (Intralipid) may be 
indicated in refractory cases, but extracorporeal membrane 
oxygenation will provide greater benefit if available.22,23
SUMMARY
Poisoning from CQ or HCQ can be life-threatening and may 
become more frequent with increased media attention and use 
during the COVID-19 pandemic. Acute toxicity is characterized 
by direct cardiotoxicity, hypokalemia, and precipitous 
cardiovascular collapse. Treatment includes aggressive 
gastrointestinal decontamination, sodium bicarbonate for QRS 
interval widening, and high-dose diazepam and epinephrine in 
patients with severe toxicity and evidence of shock. 
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Figure 2. Electrocardiogram from patient with acute hydroxychloroquine overdose demonstrating QRS interval widening (QRS 
interval = 254 milliseconds).
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